Septerna, Inc.’s (NASDAQ:SEPN) Quiet Period Set To Expire on December 4th

Septerna’s (NASDAQ:SEPN) quiet period will end on Wednesday, December 4th. Septerna had issued 16,000,000 shares in its public offering on October 25th. The total size of the offering was $288,000,000 based on an initial share price of $18.00. During Septerna’s quiet period, insiders and underwriters involved in the IPO are restricted from issuing any research reports or earnings estimates for the company because of SEC regulations. Following the end of the company’s quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

Analysts Set New Price Targets

A number of research analysts recently issued reports on SEPN shares. Wells Fargo & Company began coverage on Septerna in a report on Tuesday, November 19th. They issued an “overweight” rating and a $43.00 target price for the company. JPMorgan Chase & Co. assumed coverage on Septerna in a research note on Tuesday, November 19th. They issued an “overweight” rating and a $38.00 price objective for the company. Cantor Fitzgerald began coverage on shares of Septerna in a research note on Tuesday, November 19th. They set an “overweight” rating and a $50.00 target price on the stock. Finally, TD Cowen began coverage on shares of Septerna in a research note on Tuesday, November 19th. They issued a “buy” rating for the company.

Septerna Price Performance

SEPN stock opened at $24.28 on Wednesday. Septerna has a twelve month low of $18.62 and a twelve month high of $26.34.

Insider Activity at Septerna

In other news, major shareholder Rock Ventures V. L.P. Third acquired 370,500 shares of Septerna stock in a transaction on Monday, October 28th. The stock was bought at an average price of $18.00 per share, for a total transaction of $6,669,000.00. Following the completion of the purchase, the insider now owns 6,215,591 shares in the company, valued at $111,880,638. This represents a 6.34 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.